Alliance Pharma Regulatory News (APH)

ALLIANCE PHARMA PLC

("Alliance" or the "Company")

Block Admission Application

Alliance Pharma plc (AIM: APH), the international healthcare group, announces that it has applied for a block admission for a further 1,667,351 ordinary shares of 1p each in the Company ("Ordinary Shares") to be admitted to trading on AIM on 21 June 2022. This will be used to facilitate the admission of shares to trading following the exercise of options granted under the following two employee share schemes:

· The Alliance Pharma plc Approved Share Option Plan 2005 (up to 167,351 shares);

· The Alliance Pharma plc Long-Term Incentive Plan 2019 (up to 1,500,000 shares).

The Company will make six-monthly announcements of the utilisation of the block admission, in line with its obligations under AIM Rule 29.

New Ordinary Shares issued following option exercises and admitted to trading under the block admission will rank pari passu in all respects with the existing Ordinary Shares.

At the time of this announcement, Alliance has 539,519,338 Ordinary Shares in issue.

For further information:

About Alliance

Alliance Pharma plc (AIM: APH) is an international healthcare group. Our purpose is to improve the lives of consumers and patients through making available a range of clinically valuable healthcare products.

Our core focus is on the marketing of Consumer Healthcare brands, complemented by a smaller Prescription Medicines business. In total, we hold marketing rights to around 80 brands, with revenues generated from a mix of direct, distributor and e-commerce sales.

Headquartered in the UK, Alliance employs around 250 people based in locations across Europe, North America, and the Asia Pacific region. By outsourcing our manufacturing and logistics operations, we remain asset-light and focused on maximising the value of our brands.

For more information on Alliance, please visit our website: www.alliancepharmaceuticals.com